期刊
FRONTIERS IN PHARMACOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.978151
关键词
drugs; lung diseases; mechanisms; competition; long non-coding RNA H19
资金
- National Science Foundation of China
- National Natural Science Foundation of China [81974569]
- Joint Fund for Regional Innovation and Development
- China Postdoctoral Foundation [U20A20398]
- Collaborative Innovation Project of Universities in Anhui Province [2018M640345]
- Open project of Key Laboratory of Multimodal cognitive Computing of Anhui Province (Anhui University) [GXXT-2021-084]
- [MMC202002]
This review focuses on the regulatory role of H19 in various pulmonary diseases and collects potential therapeutic agents and molecular treatments. The aim is to demonstrate its underlying mechanism in pulmonary diseases and guide the translation of basic research targeting H19 into clinical drug development.
Non-coding RNA is still one of the most popular fields in biology research. In recent years, people paid more attention to the roles of H19 in lung diseases, which expressed abnormally in various pathological process. Therefore, this review focus on the regulatory role of H19 in asthma, pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), lung injury, pneumonia, lung cancer, etc. And the potential therapeutic agents and molecular treatments of H19 are collected. The aim is to demonstrate its underlying mechanism in pulmonary diseases and to guide the basic research targeting H19 into clinical drug translation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据